Clinical Trials Browser

Terminated × Lymphoma, Non-Hodgkin × umbralisib × Clear all

NCT03671590 2024-07-19

Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03379051 2022-08-22

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

Phase 1/2 Terminated

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02793583 2022-07-21

UNITY-NHL

Phase 2/3 Terminated

710 enrolled 1 FDA

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03207256 2022-07-21

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

Phase 2 Terminated

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02867618 2021-07-16

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

Phase 1/2 Terminated

14 enrolled 9 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin